MedTrace Logo

Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study

NCT02196701 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2018-03-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in suboptimal responders to ADA monotherapy.

Conditions

Interventions

DRUG

Adalimumab

Administered by subcutaneous injection every other week.

DRUG

Methotrexate

Methotrexate was provided as 2.5 mg tablets for oral administration.

Sponsors & Collaborators

Principal Investigators

  • Marc-André Raymond, PhD · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-05
Primary Completion
2017-03-17
Completion
2017-03-17

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02196701 on ClinicalTrials.gov